Your browser doesn't support javascript.
loading
Implementing a mHealth intervention to increase colorectal cancer screening among high-risk cancer survivors treated with radiotherapy in the Childhood Cancer Survivor Study (CCSS).
Henderson, Tara O; Bardwell, Jenna K; Moskowitz, Chaya S; McDonald, Aaron; Vukadinovich, Chris; Lam, Helen; Curry, Michael; Oeffinger, Kevin C; Ford, Jennifer S; Elkin, Elena B; Nathan, Paul C; Armstrong, Gregory T; Kim, Karen.
Afiliação
  • Henderson TO; Department of Pediatrics, The University of Chicago, Chicago, IL, USA.
  • Bardwell JK; Department of Pediatrics, The University of Chicago, Chicago, IL, USA. jbardwell@peds.bsd.uchicago.edu.
  • Moskowitz CS; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • McDonald A; St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Vukadinovich C; St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Lam H; The University of Chicago, Chicago, IL, USA.
  • Curry M; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Oeffinger KC; Duke Cancer Institute, Durham, NC, USA.
  • Ford JS; Hunter College, New York, NY, USA.
  • Elkin EB; Columbia University, New York, NY, USA.
  • Nathan PC; The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Armstrong GT; St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Kim K; The University of Chicago, Chicago, IL, USA.
BMC Health Serv Res ; 22(1): 691, 2022 May 23.
Article em En | MEDLINE | ID: mdl-35606736
BACKGROUND: Cancer survivors treated with any dose of radiation to the abdomen, pelvis, spine, or total body irradiation (TBI) are at increased risk for developing colorectal cancer (CRC) compared to the general population. Since earlier detection of CRC is strongly associated with improved survival, the Children's Oncology Group (COG) Long-Term Follow-Up Guidelines recommend that these high-risk cancer survivors begin CRC screening via a colonoscopy or a multitarget stool DNA test at the age of 30 years or 5 years following the radiation treatment (whichever occurs last). However, only 37% (95% CI 34.1-39.9%) of high-risk survivors adhere to CRC surveillance. The Activating cancer Survivors and their Primary care providers (PCP) to Increase colorectal cancer Screening (ASPIRES) study is designed to assess the efficacy of an intervention to increase the rate of CRC screening among high-risk cancer survivors through interactive, educational text-messages and resources provided to participants, and CRC screening resources provided to their PCPs. METHODS: ASPIRES is a three-arm, hybrid type II effectiveness and implementation study designed to simultaneously evaluate the efficacy of an intervention and assess the implementation process among participants in the Childhood Cancer Survivor Study (CCSS), a North American longitudinal cohort of childhood cancer survivors. The Control (C) arm participants receive electronic resources, participants in Treatment arm 1 receive electronic resources as well as interactive text messages, and participants in Treatment arm 2 receive electronic educational resources, interactive text messages, and their PCP's receive faxed materials. We describe our plan to collect quantitative (questionnaires, medical records, study logs, CCSS data) and qualitative (semi-structured interviews) intervention outcome data as well as quantitative (questionnaires) and qualitative (interviews) data on the implementation process. DISCUSSION: There is a critical need to increase the rate of CRC screening among high-risk cancer survivors. This hybrid effectiveness-implementation study will evaluate the effectiveness and implementation of an mHealth intervention consisting of interactive text-messages, electronic tools, and primary care provider resources. Findings from this research will advance CRC prevention efforts by enhancing understanding of the effectiveness of an mHealth intervention and highlighting factors that determine the successful implementation of this intervention within the high-risk cancer survivor population. TRIAL REGISTRATION: This protocol was registered at clinicaltrials.gov (identifier NCT05084833 ) on October 20, 2021.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radioterapia / Neoplasias Colorretais / Telemedicina / Detecção Precoce de Câncer / Sobreviventes de Câncer Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radioterapia / Neoplasias Colorretais / Telemedicina / Detecção Precoce de Câncer / Sobreviventes de Câncer Idioma: En Ano de publicação: 2022 Tipo de documento: Article